No price history available.
Key financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CADm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | CADm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CADm | -20 | -36 | -12 | -9 | -3 | -4 | -1 | -2 |
| EPS reported | CAD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CAD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CAD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CAD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CADm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CADm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CADm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CAD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CAD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-based technologies, designed to engage the immune system in combating viral infections. Its active development pipeline includes BETR-001, intended for major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another key asset, BETR-002, is being advanced to address benzodiazepine dependency, anxiety, and spasticity. Further in development are MM-003 for COVID-19 and other respiratory viral infections; MM-001, a topical intravaginal cream for HPV-induced cervical intraepithelial neoplasia; and AP-002, designated for cancer treatment. BetterLife Pharma Inc. maintains a research collaboration with the University of California San Diego, focusing on preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. Headquartered in Vancouver, Canada, the company was founded in 2002 and was formerly known as Pivot Pharmaceuticals Inc. before adopting the name BetterLife Pharma Inc. in December 2019.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-based technologies, designed to engage the immune system in combating viral infections. Its active development pipeline includes BETR-001, intended for major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another key asset, BETR-002, is being advanced to address benzodiazepine dependency, anxiety, and spasticity. Further in development are MM-003 for COVID-19 and other respiratory viral infections; MM-001, a topical intravaginal cream for HPV-induced cervical intraepithelial neoplasia; and AP-002, designated for cancer treatment. BetterLife Pharma Inc. maintains a research collaboration with the University of California San Diego, focusing on preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. Headquartered in Vancouver, Canada, the company was founded in 2002 and was formerly known as Pivot Pharmaceuticals Inc. before adopting the name BetterLife Pharma Inc. in December 2019.